Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Genentech, Inc.
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT01652482
First received: July 26, 2012
Last updated: November 19, 2014
Last verified: November 2014

July 26, 2012
November 19, 2014
October 2012
June 2015   (final data collection date for primary outcome measure)
Progression-free survival (tumor assessments according to RECIST v1.1 criteria) [ Time Frame: approximately 8 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01652482 on ClinicalTrials.gov Archive Site
  • Objective response rate (complete response + partial response) [ Time Frame: approximately 8 months ] [ Designated as safety issue: No ]
  • Duration of objective response [ Time Frame: approximately 8 months ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: approximately 17 months ] [ Designated as safety issue: No ]
  • Safety: Incidence of adverse events [ Time Frame: approximately 9 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics of MEHD7945A in combination with FOLFIRI: Area under the concentration-time curve (AUC) [ Time Frame: Pre-dose and 30 min after end of infusion Day 1 Cycles 1-4, pre-dose Day 1 Cycles 10 and 16 ] [ Designated as safety issue: No ]
  • Incidence of anti-MEHD7945A antibodies [ Time Frame: Pre-dose Day 1 Cycles 1 and 4, and at treatment completion ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer

This open-label, randomized, multicenter Phase II study will evaluate the safety and efficacy of MEHD7945A when combined with FOLFIRI chemotherapy as compared t

o cetuximab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal c ancer who have progressed after first-line oxaliplatin-containing chemotherapy f or metastatic disease. Patients will be randomized to receive FOLFIRI chemothera py plus either MEHD7945A (1100 mg intravenously every 2 weeks) or cetuximab (400 mg/m2 iv loading dose Day 1 Cycle 1, followed by 250 mg/m2 iv every week). Antic ipated time on study treatment is until disease progression or unacceptable toxi city occurs.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Colorectal Cancer
  • Drug: FOLFIRI
    Standard FOLFIRI (irinotecan/5-FU/leucovorin) chemotherapy every 2 weeks
  • Drug: MEHD7945A
    1100 mg iv every 2 weeks
  • Drug: cetuximab
    400 mg/m2 iv loading dose Day 1 Cycle 1, followed by 250 mg/m2 weekly
  • Experimental: A: FOLFIRI + MEHD7945A
    Interventions:
    • Drug: FOLFIRI
    • Drug: MEHD7945A
  • Active Comparator: B: FOLFIRI + cetuximab
    Interventions:
    • Drug: FOLFIRI
    • Drug: cetuximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
June 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Histologically or cytologically confirmed adenocarcinoma of the colon and/or rectum, with KRAS wild-type status
  • Progressive disease on or after first-line oxaliplatin-containing regimen for metastatic colorectal cancer; patients must have received oxaliplatin-containing chemotherapy for >/= 3 months; no more than one prior chemotherapy for metastatic disease is allowed
  • Measurable disease per RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Adequate hematologic and end-organ function

Exclusion Criteria:

  • Prior treatment with irinotecan
  • Prior treatment with an investigational or approved HER-targeted agent
  • Last anti-tumor therapy within 4 weeks prior to Cycle 1, Day 1, including chemotherapy, biologic, experimental, hormonal or radiotherapy, or not having recovered from all treatment-related toxicities (except for alopecia) to Grade </=1, with the following exceptions: oxaliplatin-containing chemotherapy within 2 weeks prior to Cycle 1, Day 1, oxaliplatin-related neuropathy that is Grade </= 2 and considered stable, and palliative radiotherapy to bone metastases within 2 weeks prior to Cycle 1, Day 1
  • Leptomeningeal disease as the only manifestation of the current malignancy
  • Active infection requiring IV antibiotics
  • Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs
  • Current severe , uncontrolled systemic disease
  • History of cardiac heart failure or serious cardiac arrhythmia requiring treatment (except for atrial fibrillation and paroxysmal supraventricular tachycardia)
  • History of myocardial infarction within 6 months prior to Cycle 1 Day 1, or history of unstable angina
  • Clinically significant GI bleeding within 6 months prior to Cycle 1 Day 1
  • History of severe (Grade 3 or 4) allergic or hypersensitivity reaction to therapeutic antibodies that required discontinuation of treatment
  • Known HIV infection
  • Untreated CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
  • Pregnant or lactating women
  • Malignancies other than colorectal cancer within 5 years prior to randomization, except for adequately treated basal or squamous cell skin cancer and carcinoma in situ of the cervix
Both
18 Years and older
No
Contact: Reference Study ID Number: GO28074 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. Only) global.rochegenentechtrials@roche.com
United States,   Australia,   Belgium,   France,   Germany,   Italy,   New Zealand,   Romania,   Spain,   United Kingdom
 
NCT01652482
GO28074, 2011-005547-27
Not Provided
Genentech, Inc.
Genentech, Inc.
Not Provided
Study Director: Clinical Trials Genentech, Inc.
Genentech, Inc.
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP